Suppression and Overexpression of Adenosylhomocysteine Hydrolase-like Protein 1 (AHCYL1) Influences Zebrafish Embryo Development

A POSSIBLE ROLE FOR AHCYL1 IN INOSITOL PHOSPHOLIPID SIGNALING

Benjamin J. Cooper†, Brian Key§, Adrian Carter§, Nicola Z. Angel‡, Derek N. J. Hart§, and Masato Kato†

From the Dendritic Cell Program, Mater Medical Research Institute, Brisbane, Queensland 4101, Australia and Discipline of Anatomy and Developmental Biology, School of Biomedical Sciences, University of Queensland, Brisbane, Queensland 4172, Australia, and the School of Medicine, University of Queensland, Herston, Queensland 4006, Australia

Adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) is a novel intracellular protein with ~50% protein identity to adenosylhomocysteine hydrolase (AHCY), an important enzyme for metabolizing S-adenosyl-L-homocysteine, the by-product of S-adenosyl-L-homomethionine-dependent methylation. AHCYL1 binds to the inositol 1,4,5-trisphosphate receptor, suggesting that AHCYL1 is involved in intracellular calcium release. We identified two zebrafish AHCYL1 orthologs (zAHCYL1A and -B) by bioinformatics and reverse transcription-PCR. Unlike the ubiquitously present AHCY genes, AHCYL1 genes were only detected in segmented animals, and AHCYL1 proteins were highly conserved among species. Phylogenetic analysis suggested that the AHCYL1 gene diverged early from AHCY and evolved independently. Quantitative reverse transcription-PCR showed that zAHCYL1A and -B mRNA expression was regulated differently from the other AHCY-like protein zAHCYL2 and zAHCY during zebrafish embryogenesis. Injection of morpholino antisense oligonucleotides against zAHCYL1A and -B into zebrafish embryos inhibited zAHCYL1A and -B mRNA translation specifically and induced ventralized morphologies. Conversely, human and zebrafish AHCYL1A mRNA injection into zebrafish embryos induced dorsalized morphologies that were similar to those obtained by depleting intracellular calcium with thapsigargin. Human AHCY mRNA injection showed little effect on the embryos. These data suggest that AHCYL1 has a different function from AHCY and plays an important role in embryogenesis by modulating inositol 1,4,5-trisphosphate receptor function for the intracellular calcium release.

We discovered human adenosylhomocysteine hydrolase-like protein 1 (hAHCYL1); previously termed dendritic cell-expressed AHCY-like protein, or DCAL) by differential display from the Hodgkin disease-derived cell line L428 (1). The hAHCYL1 protein (~60 kDa, 530 amino acids) consists of a novel N-terminal hydrophilic domain (106 amino acids) and a C-terminal domain (424 amino acids), which is homologous (51% protein identity) to the methylation pathway enzyme, AHCY (EC 3.3.1.1, ~46 kDa). AHCY is the evolutionarily conserved and ubiquitously expressed enzyme that catalyzes the reversible hydrolysis of S-adenosyl-L-homocysteine, a byproduct of the S-adenosyl-L-homomethionine-dependent methyltransferase reaction, into adenosine and homocysteine using NAD+ as a cofactor (2). Although AHCYL1 conserves the cysteines required for a tight globular structure of AHCY and the NAD+ binding motif, AHCYL1 lacks some binding sites for S-adenosyl-L-homocysteine, suggesting that AHCYL1 has a different function from AHCY. The N-terminal hydrophilic domain contains 79 polar or charged amino acids, including a cluster of Ser, Thr, and Tyr (potential phosphorylation sites), and this domain is likely to regulate AHCYL1 function (1).

AHCYL1 is highly conserved among species, and the human and mouse orthologs have 100% protein identity, suggesting a highly conserved function yet to be understood. The other AHCY-like protein KIAA0828 (termed AHCYL2 hereafter) has similar gene and protein structure to those of AHCYL1, but again its function is unknown (1, 3). In blood, hAHCYL1 mRNA was predominantly expressed in dendritic cells (DC), the most potent antigen-presenting cells for eliciting immune responses (4, 5), but not in other leukocytes. Increased hAHCYL1 mRNA expression during DC differentiation and activation suggested that hAHCYL1 plays a role in DC differentiation and function (1). However, the UniGene data base analysis (UniGene cluster Hs.4113) and our multiple tissue expression array analysis§ indicated that hAHCYL1 is also expressed in nonhematopoietic tissues, especially at high levels in neuronal and renal tissues.

Recently, Ando et al. (6) showed that AHCYL1 is identical to adenosylhomocysteine hydrolase; zAHCY, zebrafish AHCY; hAHCY, human AHCY; DC, dendritic cells; EGFP, enhanced green fluorescent protein; EST, expressed sequence tag; GPDH, glyceroldehyde-3-phosphate dehydrogenase; hpf, hours postfertilization; IP5, inositol 1,4,5-trisphosphate; IP6, inositol 1,4,5,6-trisphosphate receptor; RACE, rapid amplification of cDNA ends; RT, reverse transcription; E1–E20, exon 1–20, respectively.

† To whom correspondence should be addressed: Mater Medical Research Institute, Aubigny Pl, South Brisbane, Queensland 4101, Australia. Tel.: 61-7-3840-2555; Fax: 61-7-3840-2550; E-mail: mkato@mmedi.mater.org.au.

§ The abbreviations used are: hAHCYL, human AHCYL; zAHCYL, zebrafish AHCY; AHCYL, adenosylhomocysteine hydrolase-like protein; AHCY, adenosylhomocysteine hydrolase; zAHCY, zebrafish AHCY; hAHCY, human AHCY; DC, dendritic cells; EGFP, enhanced green fluorescent protein; EST, expressed sequence tag; GPDH, glyceroldehyde-3-phosphate dehydrogenase; hpf, hours postfertilization; IP5, inositol 1,4,5-trisphosphate; IP6, inositol 1,4,5,6-trisphosphate receptor; RACE, rapid amplification of cDNA ends; RT, reverse transcription; E1–E20, exon 1–20, respectively.

3 B. J. Cooper, unpublished results.
an inositol 1,4,5-trisphosphate receptor (IP$_3$R)-binding protein (termed IP$_3$R-binding protein released with inositol 1,4,5-trisphosphate, or IRBIT). Binding of AHCYL1 to IP$_3$R, an important regulator of intracellular Ca$^{2+}$ release, is mediated by its N-terminal domain, and its phosphorylation appears to be essential for the AHCYL1 binding. Importantly, the AHCYL1 binding site on IP$_3$R also mediates the IP$_3$-IP$_3$R interaction, suggesting that AHCYL1 regulates IP$_3$ binding to the IP$_3$R. The consequence of AHCYL1 interacting with the IP$_3$R remains to be elucidated, but it is of significant interest given the important regulating role other molecules (and other signaling pathways) have on Ca$^{2+}$ as a result of IP$_3$R activation.

To investigate the function of AHCYL1, we chose the zebrafish (Danio rerio) as a model organism for molecular genetic analysis. We describe the cDNA cloning and genomic organization of the zAHCYL1, compare them with those of hAHCYL1 and other AHCYL1 homologs, and demonstrate the effect of suppression and overexpression of AHCYL1 on zebrafish development.

**EXPERIMENTAL PROCEDURES**

*In Silico Cloning of zAHCYL1—Expressed sequence tags (ESTs) corresponding to zAHCYL1 were identified in the dbEST data base from the National Center for Biotechnology Information (NCBI) by performing a BLASTn search using hAHCYL1 coding sequence as the query. Nine overlapping ESTs (GenBankTM accession numbers CA473816, BI473660, hAHCYL1 coding sequence as the query. Nine overlapping ESTs (GenBankTM accession numbers CA473816, BI473660, BI885096, CD284541, BI430354, BI884776, BI473380, CD594351, and BF937243) were compiled using Sequencer software (Gene Codes, Ann Arbor, MI) to form a putative zAHCYL1 cDNA sequence. This sequence was used to design primers for cloning the full-length zAHCYL1 cDNA (described below). Exon/intron boundaries were determined via a zebrafish genomic BLAST search available from the Ensembl Zebrafish Genome Server.*

Identification of AHCYL1 in Other Species—AHCYL1 orthologs in other species were identified by tBLASTn searches using hAHCYL1 protein sequence for enquiry on the NCBI genomic or EST data bases. Searches were conducted in the following organisms (data base used is shown in parentheses): Anopheles gambiae (genome), Caenorhabditis elegans (genome), Drosophila melanogaster (genome), Takifugu rubripes (genome), Gallus gallus (EST), Plasmodium falciparum (genome), Saccharomyces cerevisiae (genome), Xenopus laevis (EST), and the microbial genome database (completed genomes only). To confirm that output sequences were AHCYL family orthologs and not ACY orthologs, the sequences were assessed for (i) N-terminal domain containing conserved Ser/Thr residues and (ii) alignment with the hAHCY protein using NCBI pairwise BLAST indicating less similarity to hAHCY than hAHCYL1. Phylogenetic analysis was performed using the programs ClustalW for multiple sequence alignment and ProtDix for computing the phylogenic tree and bootstrap values with 100 bootstrap cycles. Both programs are available on the Australian National Genomic Information Service Bioinformatics service (ANGIS; available on the World Wide Web at www.angis.org.au). The protein sequences included were AHCYL1 orthologs from human (GenBankTM accession number AF315687), zebrafish (GenBankTM accession number AFY611473, this report), fugu fish (GenBankTM accession number BK005364; this report), and fruit fly (GenBankTM accession number NM_139489 and NM_206499); AHCYL2 orthologs from human (GenBankTM accession number NM_015328) and zebrafish (GenBankTM accession number NM_000687); mouse (GenBankTM accession number BC086781), zebrafish (GenBankTM accession number BC044200), and fruit fly (GenBankTM accession number NM_078609).

**Prediction of Phosphorylation Sites and NAD+ Binding Domain**—Potential Ser/Thr/Tyr phosphorylation sites in the AHCYL1 protein sequences were assessed using the program NetPhos 2.0 (7) on the ExPasy Molecular Biology server (available on the World Wide Web at au.expasy.org). The AHCY NAD$^{+}$ binding region of the AHCYL1 proteins was defined using the Conserved Domain Database through NCBI.

**RT-PCR Cloning of zAHCYL1**—Total RNA was isolated from adult zebrafish head extracted with Trizol (Invitrogen) and 5’-rapid amplification of cDNA ends (RACE) for zAHCYL1 using the FirstChoice RLM RACE kit (Ambion, Austin, TX) carried out according to the manufacturer’s instructions. First strand cDNA synthesis was carried out using 10 μg of the total RNA, and the primary PCR was performed using the outer adaptor primer (5’-GCTGATGGCGATGAACTGGT-3’) and the gene-specific outer primer MK279 (5’-GCTGAGCTTAGCTGTTCCGTA-3’), nucleotides 508–528 of zAHCYL1A) using AmpliTaq Gold (Applied Biosystems, Scoresby, Victoria, Australia). The primary PCR product was further amplified using the inner adaptor primer (5’-GGGAATCCGATCCGAGTACACCCTGAGTCTGTTCCGTA-3’) and the gene-specific inner primer MK280 (5’-TCTTTGTGGTTGCTCTCTCTGTT-3’, nucleotides 425–444 of zAHCYL1A) (see Fig. 1). The PCR was performed on a PTC 200 thermal cycler (M Research, Waltham, MA) with the following reaction cycle: 94°C for 10 min; 35 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s; 72°C for 10 min.

Cloning of full-length zAHCYL1 coding sequence was performed using a Thermoscript RT-PCR system (Invitrogen). Briefly, 1 μg of total RNA from adult zebrafish head was subjected to first strand cDNA synthesis using oligo(dT)$_{20}$ reverse primer. To obtain full-length zAHCYL1 coding regions, gene-specific primers nested to the zAHCYL1 5’- and 3’-untranslated region were synthesized: MK350 (5’-CGACA-GCTTTTGTTCTTCCCT-3’) and MK352 (5’-AAGAGCCTCA-GGCGCACAGACA-3’), corresponding to exon 1 (nucleotides 58–77) and exon 2 (nucleotides 9–28), respectively, as the forward primers and MK351 (5’-AAGCCACACAGACATCTTTT-3’), corresponding to nucleotides 2288–2310, as the nested reverse primer. PCR products were cloned into pGEM-T Easy vector (Promega, Annandale, New South Wales, Australia) for sequencing.

**Identification of Alternatively Spliced hAHCYL1**—Alternative N-terminal splicing of hAHCYL1 was identified in humans using the dbEST data base available from NCBI. In order to identify sequences of authentic splice variants, we searched for ESTs that (i) contained sequence that overlapped substantially
with known hAHCYL1 cDNA and (ii) could be mapped to the chromosome band 1p12 for the hAHCYL1 gene (1).

Quantitative RT-PCR—Total RNA purified from zebrafish embryos at different stages of development (50–100 embryos/stage) using Trizol (Invitrogen) was treated with DNase I (Invitrogen) to remove contaminating genomic DNA and subjected to cDNA synthesis with random hexamers using Expand reverse transcriptase (Roche Applied Science). For quantitative RT-PCR analysis, the cDNA was combined with gene-specific forward and reverse primers for zAHCYL1A, zAHCYL1B, zAHCYL2, and zAHCY and a SYBR green master mix (QuantiTect SYBR PCR kit, Qiagen, Clifton Hill, Victoria, Australia) and subjected to real time PCR using a Rotorgene 3000 thermal cycler (Corbett Research, Mortlake, New South Wales, Australia). Zebrafish glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for normalization of cDNA input. The primers were zAHCYL1A, MK279, and MK391 (5'-ACACGGAGGTGAACATGAAC-3'); zAHCYL1B, MK279, and MK352; zAHCYL2, MK388 (5'-TCTTGGTGGGACCTTGGTTG-3'), and MK390 (5'-ACCAGGCCCCATGAAGAT-3'); and zebrafish GAPDH, MK293 (5'-CCCAATGTCTCGTGTGGA-3'), and MK294 (5'-CGTGTAGACATAACAGCA-3').

Production of Rabbit Anti-AHCYL1 Peptide Antibody—Rabbit polyclonal peptide antiserum against the AHCYL1 C-terminal peptide were produced by immunizing New Zealand White rabbits with diphertheria toxoid-conjugated synthetic peptide CGPFKPNYYRY (Mimotopes, Clayton, Victoria, Australia) using a conventional schedule with Freund adjuvant at the Herston Medical Research Center (Herston, Queensland, Australia). The titer of the antibody against the peptide was assessed using a conventional schedule with Freund adjuvant at the Herston Medical Research Center (Herston, Queensland, Australia). The titer of the antibody against the peptide was assessed using a conventional schedule with Freund adjuvant at the Herston Medical Research Center (Herston, Queensland, Australia).

Morpholino Antisense Oligonucleotides against AHCYL1 for Microinjection—The morpholino antisense oligonucleotides M01A (5'-TGGCATCCTCGCCACGTCGTTCAT-3') and M01B (5'-CATGGTTCTTGCTCCTGGTGTTG-3') against zAHCYL1A and zAHCYL2 (see Fig. 1), and a standard control morpholino antisense oligonucleotide (5'-CCTCTTA-CCGCTTACACCTTTACA-3') were obtained from Gene Tools (Philomath, OR). Zebrafish embryos at the 1–2-cell stage were microinjected (0.5 nl/embryo) with the morpholino oligonucleotides (1, 0.5, or 0.2 mM) mixed with synthetic capped enhanced green fluorescent protein (EGFP), E1/EGFP, or E2/EGFP mRNA (0.125 mg/ml, described below).

Production of pCS2-hAHCYL1, pCS2-hAHCY, and pCS2-zAHCYL1 mRNA Synthesis Vectors—The cDNAs of human and zebrafish AHCYL1 and human ACY cDNA, including 5'- and 3'-untranslated regions were cloned into the pcDNA2 + expression vector (10). Briefly, hAHCYL1A sequence was excised from the clone 211(1)B (1) using XbaI and SacI, and ligated into the corresponding sites available in pcDNA2 + to generate pcDNA-hAHCYL1A. The human ACY cDNA was amplified using RT-PCR from pooled human cDNA (from monocyte-derived dendritic cells and cell lines (i.e. L428 and HL60)) using primers MK276 (5'-CGGCCCAGTCTCTTCTGGC-3') and MK277 (5'-GCTTACGTCCTGGTGTCG-3') using a Taq polymerase (Roche Applied Science). The PCR product was cloned into pGEM-T Easy vector for sequence confirmation. The insert was excised with NotI and SpeI, NotI site-bluented, and subcloned into pcDNA+ with blunted BstXI and SpeI sites. The zAHCYL1A sequence was derived from the pGEM-T Easy vector clone (described above) and cloned into pcDNA+ using a strategy similar to that described for the human ACY clone. All plasmids were linearized with NotI for in vitro mRNA synthesis.

Production of pcDNA2-E1/EGFP and pcDNA2-E2/EGFP mRNA Synthesis Vectors—zAHCYL1 cDNAs encoded by the exon 1 and exon 2 were PCR-amplified with Pfu polymerase (Stratagene, La Jolla, CA) using sets of primers MK350/MK380 (5'-GCACCATGGGCTCTGGGTGCAATT-3', NcoI site underlined) for exon 1 and MK352/MK382 (5'-GCATCTACGCTCTGGGTGCAATT-3', RcaI site underlined) for exon 2, respectively (see Fig. 1). The PCR products were cloned into pcDNA+ digested with SmaI/NcoI or SmaI/RsaI so that the cloned exons were in frame with EGFP.

Capped mRNA Synthesis and Microinjection—Capped mRNA was synthesized using a SP6 mMessage mMACHINE kit (Ambion, Austin, TX). EGFP (an injection control) mRNA was prepared as described previously (10). RNA was purified by phenol/chloroform extraction followed by ethanol precipitation and resuspended to a concentration at 1.5 mg/ml, and integrity was checked by formaldehyde denaturing gel electrophoresis. Zebrafish embryos at the 1–2-cell stage were microinjected (0.5 nl/embryo) with the synthesized mRNA (1 mg/ml) mixed with EGFP mRNA (0.125 mg/ml). Only EGFP-positive embryos were examined at 12–28 hpf and scored according to the severity of their morphological
Role of AHCYL1 on Zebrafish Development

(A) 5'-RACE Inner PCR

(B) Zebrafish AHCYL1A

(C) Zebrafish AHCYL1B
defects. Embryos injected with EGFP mRNA at 1.2 mg/ml were used as injection controls.

**Depletion of Intracellular Calcium Stores**—Thapsigargin treatment of embryos was performed according to Westfall et al. (11). Briefly, a 5 mM thapsigargin (Sigma) stock solution was made in Me2SO. 32–64-cell stage embryos were incubated with 5 mM thapsigargin diluted in egg medium (8). Me2SO-only incubations were used as a negative control. After a 1-h incubation, embryos were washed extensively in egg medium and incubated at 28°C in embryo media until required.

**Western Blot Analysis**—Zebrafish embryos (1–2-cell stage) were injected with synthetic hAHCYL1, zAHCYL1, or hAHCY mRNA (1.5 mg/ml) in combination with EGFP mRNA and incubated for 6 h. EGFP-positive embryos were harvested and lysed with 1% Triton X-100, 50 mM Tris-HCl, pH 7.4, and a protease inhibitor mixture (Complete; Roche Applied Science), 1 mM phenylmethylsulfonyl fluoride (Sigma), and 5 mM EDTA, and the lysate was cleared by centrifugation at 20,000 × g for 10 min at 4°C. The protein concentration was determined by a BCA protein assay (Pierce) using bovine serum albumin as standard. The lysate was aliquoted and stored at −70°C until use. For positive controls, COS-7 cells in two 100-mm dishes were transfected with pCS2-hAHCYL1 or pCS2-hAHCY (5 μg/dish) using Fugene 6 (Roche Applied Science) according to the manufacturer's protocol and incubated for 48 h. The cells were lysed with the lysis buffer, and protein concentration was determined as above.

The lysate from the zebrafish embryos (250 μg) and COS-7 cell transfectants (20 μg) was fractionated with a 4–12% gradient SDS-polyacrylamide gel (NuPAGE; Invitrogen) in reducing conditions and transferred onto a polyvinylidene difluoride membrane (PVDF-Plus, Osmonics, Westborough, MA). The membrane was blocked with 5% nonfat skim milk, 0.1% Tween 20 (Sigma) in phosphate-buffered saline and incubated with the rabbit anti-AHCYL1 peptide antibody (5 μg/ml) and horseradish peroxidase-conjugated goat anti-rabbit IgG (1:5000 dilution; Chemicon, Boronia, Victoria, Australia) and the signals detected with enhanced chemiluminescence (Pierce).

**RESULTS**

**Cloning of zAHCYL1 and Its Genomic Organization**—The AHCYL1 gene is highly conserved among species (e.g. 100% protein identity), and it is encoded by three alternative 5′-untranslated sequences. The alternative splicing produces three variant mRNAs (AHCYL1A, B, and C), only two variant proteins are produced, because both exon 2/3 and exon 4 encode only 5′-untranslated sequence, and the translation start site appears to be within the common exon 5. aa, amino acids.
Role of AHCYL1 on Zebrafish Development

Identity between human and mouse (1). To clone the zAHCYL1, we conducted a BLAST search using the coding sequence for hAHCYL1 cDNA (GenBank™ accession number AF315687) to search the NCBI zebrafish EST data base. The ESTs obtained were aligned to establish a consensus zAHCYL1 cDNA sequence, which was confirmed by RT-PCR and DNA sequencing.

To determine the transcriptional start site on zAHCYL1 mRNA, we performed 5′-RACE analysis using primers...
nested in the 5′-zAHCYL1 cDNA in the adult zebrafish head-derived cDNA library. This resulted in two PCR products (~450 and 250 bp) (Fig. 1A). Sequencing analysis revealed that these two products corresponded to two zAHCYL1 mRNA variants with mutually exclusive transcription start sites termed zAHCYL1A and zAHCYL1B (Fig. 1, B and C). The zAHCYL1A sequence corresponded to the zAHCYL1 sequence obtained by EST data base search and confirmed using RT-PCR (Fig. 1B). This was identified as the ortholog of hAHCYL1 (described below). The zAHCYL1B sequence contained a previously uncharacterized 46-bp alternative 5′-untranslated region plus an alternative coding sequence for the N-terminal 9 amino acids, assuming that the first ATG in the sequence is the initiation codon (Fig. 1C). These results suggested that at least two alternatively spliced variants of zAHCYL1 were present.

To determine the full genomic structure of zAHCYL1A and -B, we performed a BLAST search of the Ensembl zebrafish spliced variants of zAHCYL1 were present. The putative initiation codon was identified by comparing the genomic sequence with these cDNA sequences. We found the zAHCYL1 gene consisted of 18 exons spanning 39 kb (Fig. 2A). The zAHCYL1B transcript was encoded by 17 exons (with exon 2 spliced out), and the last 15 exons encoded the AHCY-like domain, similar to hAHCYL1. The zAHCYL1B transcript is also encoded by 17 exons but uses exon 2, located 9.2 kb downstream of exon 1, as an alternative first exon.

The putative zAHCYL1A protein (encoded by exons 1 and 3–18) consists of 554 amino acids with an N-terminal hydrophilic domain (130 amino acids; exons 1, 3, and 4) and an AHCY-like domain (424 amino acids; exons 4–18) (Fig. 2B). The putative initiation codon was identified by comparing the zAHCYL1 protein to that of T. rubripes AHCYL1 protein (assigned GenBank accession number BK005364). The zAHCYL1B protein (exons 2 and 3–18) consists of 500 amino acids with the N-terminal hydrophilic domain being only 76 amino acids (exons 2–4) (Fig. 2B). Its initiation codon was identified as the first methionine in exon 2.

Next we investigated possible alternative usage of 5′ exons in hAHCYL1 (now termed hAHCYL1A). By carrying out an extensive analysis of human EST sequences, we identified two ESTs encoding previously uncharacterized, alternatively spliced hAHCYL1 mRNAs termed hAHCYL1B and -C (Fig. 2C). hAHCYL1B was represented by two ESTs (GenBank accession numbers T19009 and B1460083) encoded by two separate exons (i.e. exons 2 and 3) joined to exon 5 (Fig. 2C). hAHCYL1C was represented by three ESTs (GenBank accession numbers AU279527, AL036027, and BF930049), which contained another alternative exon 4 (Fig. 2C). These three newly identified exon sequences (exons 2–4) could be joined by proper intron/exon junctions to exon 5. However, the only putative initiation codon appeared in exon 5, suggesting that these exons encoded alternative 5′-untranslated regions for truncated hAHCYL1 proteins, which lacked nearly half of the N-terminal hydrophilic domain (Fig. 2D).

**AHCYL1 Protein Is Evolutionarily Conserved among Species**—We used phylogenetic analysis to assess the evolutionary relationships between the orthologs of AHCYL1, AHCY, and the other member of the AHCY-like protein family in zebrafish, zAHCYL2 (GenBank accession number AAH5951), a possible ortholog of hAHCYL2 (GenBank accession number BC24325) (3). The AHCYL1 genes were distinguished from AHCY genes, suggesting that AHCYL1 diverged early from AHCY and evolved separately (Fig. 3A). Furthermore, both zebrafish and human AHCLY2 were more closely related to AHCYL1 than AHCY. Fruit fly AHCY-like proteins (CG9977 and AHCY89E), which also have an N-terminal hydrophilic domain and an AHCY-like domain, clustered with AHCYL1 and AHCLY2.

The amino acid comparison between the human and zebrafish AHCYL1A proteins show 93% identity and 97% similarity, across the region encoded by human exons 5–20 and the zebrafish exons 3–18 (Fig. 3B). Comparison with additional AHCYL1B orthologs (from mouse, fugu fish, and fruit fly) confirmed that the AHCY-like domains, including the NAD + binding domains (161 amino acids) were highly conserved in the AHCYL1 orthologs (Fig. 3B). In addition to highly conserved Cys, 27 predicted Ser/Thr/Tyr phosphorylation sites were conserved among all vertebrates analyzed, 16 of which were clustered in the N-terminal hydrophilic domain (Fig. 3B). The majority of these Ser/Thr/Tyr residues were also conserved in the fruit fly AHCY1 protein. The protein sequences encoded by exon 1 are highly diverse between species, with zAHCYL1 proteins being a 24 amino acids longer than hAHCYL1 at the N terminus. These data suggest that Ser/Thr/Tyr phosphorylation and NAD + binding are likely to play an important role in AHCYL1 function.

**zAHCYL1A and -B and zAHCYL2 mRNA Are Regulated during Embryogenesis**—We investigated the expression of zAHCYL1A and -B, zAHCYL2 and zAHCY mRNA in developing zebrafish embryos by real time RT-PCR (Fig. 4). The AHCYL1A was first apparent at the shield stage of embryos, and its expression was the highest during the 25-somite stage. At 24 hpf, its expression decreased markedly to half that of the 25-somite stage. zAHCYL1B mRNA expression peaked at the 25-somite stage. zAHCYL2 and zAHCY mRNA expression peaked at the 25-somite stage.
increased from very low levels at the shield stage, peaking at the bud stage. Its expression then decreased to very low levels by the 15-somite stage and remained low until 25 hpf.

**zAHCYL1B mRNA expression levels were much lower overall than those of zAHCYL1A (≈20%).** In contrast to the regulation of zAHCYL1A and -B mRNA during development, zAHCY mRNA was present before cell division and expressed at much higher levels in developing embryos. Its increase throughout development was consistent with the proposed role of zAHCY as a housekeeping gene. Finally, zAHCYL2 mRNA was also present before cell division at high levels and remained so until the 15-somite stage before decreasing markedly at the 25 hpf stage to levels similar to zAHCYL1A. These data indicated that zAHCYL1A and -1B expression underwent significant regulation and that both were likely to be important in zebrafish embryogenesis.

**Suppression of zAHCYL1A and -B by the Morpholino Antisense Oligonucleotides Induces Ventralized Morphologies in Zebrafish Embryos**—To investigate the function of zAHCYL1A and B in developing embryos, we used morpholino antisense oligonucleotides against zAHCYL1A and -B. First, we examined the specificities of the morpholino oligonucleotides by injecting the synthetic fusion mRNAs containing zAHCY1 exon 1 (E1/EGFP mRNA, zAHCYL1A-specific) or exon 2 (E2/EGFP mRNA, zAHCYL1B-specific) fused in frame with EGFP and the gene-specific morpholinos (MO1A and MO1B for zAHCYL1A and -B, respectively) into 1–2-cell stage embryos.
zebrafish embryos. The embryos were incubated overnight, and the gene-specific morpholino effects were assessed by the EGFP expression levels in the embryos. As shown in Fig. 5, MO1A suppressed the translation of the E1/EGFP mRNA completely, but not that of the E2/EGFP mRNA. Conversely, MO1B abolished E2/EGFP mRNA translation, but not that of E1/EGFP mRNA translation, indicating that MO1A and MO1B could inhibit specifically zAHCYL1A and -B translation, respectively.

When MO1A at 1 mM were injected into 1–2-cell stage zebrafish embryos and incubated overnight, the resultant embryos were often necrotic, and the surviving embryos showed severe and gross body axis deformities (Fig. 6A, Table 1). Injection of the MO1A at 0.5 mM produced a ventralized morphology, with abnormally developed and necrotic brain structures and expanded ventral tail fin tissue (Fig. 6B). Injection of further diluted MO1A had no morphological effect (data not shown). Injection of 1 mM or 0.5 mM MO1B resulted in similar numbers of severely deformed embryos (Fig. 6A). Injection of MO1B diluted further to 0.2 mM produced a ventralized morphology similar to that observed with the 0.5 mM MO1A injections (Fig. 6B). The apparent potency of MO1B compared with MO1A may be because zAHCYL1B mRNA was less abundant (see Fig. 4). Embryos injected with a control morpholino at 1 mM showed no abnormal morphologies. The similar morphologies, which were observed after the MO1A and MO1B injections, suggested that zAHCYL1A and -B have similar functions.

Microinjected Synthetic hAHCYL1A and hAHCY mRNA Are Translated into Cognate Proteins in Zebrafish Embryos—The zAHCYL1 antisense morpholino studies showed that AHCYL1 might play a role in dor salization, and the mRNA expression data suggested that its function was different from that of AHCY (see Fig. 4). Therefore, we hypothesized that AHCYL1 overexpression in zebrafish embryos would induce dorsalized phenotypes and that this outcome would differ from that resulting from AHCY overexpression. To test this, we first investigated the translation of the injected synthetic mRNAs into the cognate proteins. The capped mRNA encoding hAHCYL1A and hAHCY, synthesized using pCS2-hAHCYL1A and pCS2-hAHCY as templates, were injected into 1–2-cell stage zebrafish embryos. The embryos were incubated for 6 h, lysed in a lysis buffer, and subjected to Western blot analysis using the anti-hAHCYL1 peptide antibody, which binds to both AHCYL1 and hAHCY. As shown in Fig. 7, the embryos injected with the hAHCYL1A mRNA expressed a substantial 58.7-kDa

![FIGURE 6. zAHCYL1 gene knockdown by MO1A or MO1B injection induces ventralization in zebrafish embryos. A, zebrafish embryos were injected with 1 mM MO1A or -1B and observed at 24 hpf. B, zebrafish embryos were injected with 0.5 mM MO1A or 0.2 mM MO1B and observed at 24 hpf. The standard control MO did not induce any gross phenotypes. The arrowheads and arrows indicate necrotic heads and expanded ventral tail fins, respectively. Magnification for whole embryos is ×25; magnification for partial embryos is ×50.](image-url)
Role of AHCYL1 on Zebrafish Development

TABLE 1
Summary of zebrafish morphologies after mRNA injection of morpholino oligonucleotides against zAHCYL1A and -B

| Treatment | n  | Necrotized | Abnormal | Normal   |
|-----------|----|------------|----------|----------|
| 1 mM MO1A | 110| 5 (4.5%)   | 102 (92.7%) | 3 (2.7%) |
| 0.5 mM MO1A | 30 | 0 (0%)     | 24 (80%)  | 6 (20%)  |
| 0.2 mM MO1A | 49 | 0 (0%)     | 2 (4.1%)  | 47 (95.9%) |
| 1 mM MO1B | 70 | 56 (80%)   | 11 (15.7%) | 3 (4.3%) |
| 0.2 mM MO1B | 52 | 11 (21.2%) | 41 (78.8%) | 0 (0%)  |
| Standard   | 73 | 0 (0%)     | 4 (5.4%)  | 69 (94.5%) |
| control MO | 111| 0 (0%)     | 2 (1.8%)  | 109 (98.2%) |

FIGURE 7. Translation of injected synthetic mRNA in zebrafish embryos. Zebrafish embryos (1–2-cell stage) were injected with synthetic hAHCYL1 and hAHCY mRNA and incubated for 6 h. The embryos were lysed and subjected to Western blot analysis for the cognate proteins. Cell lysate from COS-7 cells transfected with hAHCYL1 or hAHCY expression vector was used as positive control. The single and double asterisks indicate the position of endogenous zAHCYL1 and zAHCY, respectively. Molecular mass standards are indicated on the right.

Table 2. Embryos injected with zAHCYL1A mRNA displayed morphological defects similar to those with hAHCYL1 expression. At the segmentation period, the moderately affected embryos (C1–C3) displayed a protruding tail bud similar to that seen in hAHCYL1 mRNA-injected embryos (Fig. 8B). Unlike hAHCYL1 mRNA-injected embryos, the head shape appeared to be normal in zHCYL1 mRNA-injected embryos. Interestingly, the transient Kupffer’s vesicle appears enlarged in zAHCYL1A mRNA-injected embryos. At the pharyngula stage, embryos displayed a shortened and kinked tail structure similar to that observed with hAHCYL1 mRNA-injected embryos (Fig. 8H). Those embryos with a moderate dorsalized morphologies (C1–C3) showed reduced circulation (data not shown), thickened/split notochord, and loss of ventral tail tissue (Fig. 9). More severely affected embryos exhibited severe dorsalization (C4–C5 grade) characterized by complete loss of posterior structure and severely reduced anterior structure (Fig. 8C; see below) with a duplicated axis also evident in some embryos (Fig. 8C, higher magnification). These hAHCYL1 mRNA-induced morphological defects were consistent with the features associated with dorsalization (12). Only 1% of embryos injected with EGFP mRNA showed abnormalities, indicating that the morphological defects in hAHCYL1 mRNA-injected embryos were specific to hAHCYL1 overexpression. In contrast, the majority of hAHCY mRNA-injected embryos displayed normal conversion extension movement comparable with the wild type at segmentation stage, indicating that gastrulation movements during segmentation were not disrupted (Fig. 8, B and G). These data suggested that AHCYL1A differed from AHCY in function.

It was possible that differences in protein structure (mostly localized at the N-terminal hydrophilic domain) between human and zebrafish AHCYL1A mediated species-specific function of AHCYL1A. Thus, we examined the effect of zAHCYL1A overexpression during embryogenesis (Fig. 8 and Table 2). Embryos injected with zAHCYL1A mRNA displayed marked morphological defects, which were categorized based on the severity according to Mullins et al. (12) (Table 2). During the segmentation stage, the moderately affected embryos (C1–C3 grade) were characterized by a shortened protruding tail bud. The tail bud did not extend around the yolk as in wild type but rather protruded from the yolk sac and was slightly enlarged (Fig. 8E). The heads of these embryos were also slightly enlarged, often exhibiting a prominent square shape. These embryos also exhibited an increase in the distance between the head and tail bud, suggesting inhibition of convergent extension movement (Fig. 8E). At the pharyngula stage, the majority of hAHCYL1A mRNA-injected embryos displayed prominent tail shortening/kinking defects (Fig. 8C). Severely affected embryos (C4–C5 grade) had more pronounced changes characterized by a complete loss of posterior structure and severely reduced anterior structure (Fig. 8C; see below) with a duplicated axis also evident in some embryos (Fig. 8C, higher magnification). These hAHCYL1 mRNA-induced morphological defects were consistent with the features associated with dorsalization (12). Only 1% of embryos injected with EGFP mRNA showed abnormalities, indicating that the morphological defects in hAHCYL1 mRNA-injected embryos were specific to hAHCYL1 overexpression. In contrast, the majority of hAHCY mRNA-injected embryos displayed normal conversion extension movement comparable with the wild type at segmentation stage, indicating that gastrulation movements during segmentation were not disrupted (Fig. 8, B and G). These data suggested that AHCYL1A differed from AHCY in function.

It was possible that differences in protein structure (mostly localized at the N-terminal hydrophilic domain) between human and zebrafish AHCYL1A mediated species-specific function of AHCYL1A. Thus, we examined the effect of zAHCYL1A overexpression during embryogenesis (Fig. 8 and Table 2). Embryos injected with zAHCYL1A mRNA displayed morphological defects similar to those with hAHCYL1 expression. At the segmentation period, the moderately affected embryos (C1–C3) displayed a protruding tail bud similar to that seen in hAHCYL1 mRNA-injected embryos (Fig. 8F). Unlike hAHCYL1 mRNA-injected embryos, the head shape appeared to be normal in zHCYL1 mRNA-injected embryos. Interestingly, the transient Kupffer’s vesicle appears enlarged in zAHCYL1A mRNA-injected embryos. At the pharyngula stage, embryos displayed a shortened and kinked tail structure similar to that observed with hAHCYL1 mRNA-injected embryos (Fig. 8H). Those embryos with a moderate dorsalized morphologies (C1–C3) showed reduced circulation (data not shown), thickened/split notochord, and loss of ventral tail tissue (Fig. 9). More severely affected embryos exhibited severe dorsalization (C4–C5 grade) characterized by complete loss of posterior structure as seen in hAHCYL1A mRNA-injected embryos (Fig. 8H), suggesting that function of AHCYL1A orthologs was largely conserved among species.

Dorsalized morphologies of zebrafish embryos were evident when the phosphatidylinositol cycle was inhibited (11). The phosphatidylinositol cycle is responsible for generating IP₃R-dependent intracellular Ca²⁺ release through the action of a second messenger, IP₃ (13). Because AHCYL1 binds to the IP₃R protein band corresponding to the hAHCYL1 protein, compared with the embryos injected with the hAHCY mRNA or to un.injected control embryos. The hAHCYL1 protein translated in zebrafish embryos was the same size as the AHCYL1 protein expressed in the COS-7 cells transiently transfected with the pCS2-hAHCYL1. The hAHCY mRNA was also translated into the protein in the zebrafish embryos; however, the expression levels did not change markedly because of high levels of endogenous zAHCY.

Microinjection of AHCYL1A mRNA Induces Dorsalized Morphologies in Zebrafish Embryos—The high levels of conservation of AHCYL1A proteins between species suggested that these proteins may have similar cross-species function. We injected the synthetic hAHCYL1A mRNA and hAHCY into the 1–2-cell stage zebrafish embryos and examined them after overnight incubation (Figs. 8 and 9). Those embryos injected with hAHCYL1A mRNA displayed marked morphological defects, which were categorized based on the severity according to Mullins et al. (12) (Table 2). During the segmentation stage, the moderately affected embryos (C1–C3 grade) were characterized by a shortened protruding tail bud. The tail bud did not extend around the yolk as in wild type but rather protruded from the yolk sac and was slightly enlarged (Fig. 8E). The heads of these embryos were also slightly enlarged, often exhibiting a prominent square shape. These embryos also exhibited an increase in the distance between the head and tail bud, suggesting inhibition of convergent extension movement (Fig. 8E). At the pharyngula stage, the majority of hAHCYL1A mRNA-injected embryos displayed prominent tail shortening/kinking defects (Fig. 8C). Severely affected embryos (C4–C5 grade) had more pronounced changes characterized by a complete loss of posterior structure and severely reduced anterior structure (Fig. 8C; see below) with a duplicated axis also evident in some embryos (Fig. 8C, higher magnification). These hAHCYL1 mRNA-induced morphological defects were consistent with the features associated with dorsalization (12). Only 1% of embryos injected with EGFP mRNA showed abnormalities, indicating that the morphological defects in hAHCYL1 mRNA-injected embryos were specific to hAHCYL1 overexpression. In contrast, the majority of hAHCY mRNA-injected embryos displayed normal conversion extension movement comparable with the wild type at segmentation stage, indicating that gastrulation movements during segmentation were not disrupted (Fig. 8, B and G). These data suggested that AHCYL1A differed from AHCY in function.

It was possible that differences in protein structure (mostly localized at the N-terminal hydrophilic domain) between human and zebrafish AHCYL1A mediated species-specific function of AHCYL1A. Thus, we examined the effect of zAHCYL1A overexpression during embryogenesis (Fig. 8 and Table 2). Embryos injected with zAHCYL1A mRNA displayed morphological defects similar to those with hAHCYL1 expression. At the segmentation period, the moderately affected embryos (C1–C3) displayed a protruding tail bud similar to that seen in hAHCYL1 mRNA-injected embryos (Fig. 8F). Unlike hAHCYL1 mRNA-injected embryos, the head shape appeared to be normal in zHCYL1 mRNA-injected embryos. Interestingly, the transient Kupffer’s vesicle appears enlarged in zAHCYL1A mRNA-injected embryos. At the pharyngula stage, embryos displayed a shortened and kinked tail structure similar to that observed with hAHCYL1 mRNA-injected embryos (Fig. 8H). Those embryos with a moderate dorsalized morphologies (C1–C3) showed reduced circulation (data not shown), thickened/split notochord, and loss of ventral tail tissue (Fig. 9). More severely affected embryos exhibited severe dorsalization (C4–C5 grade) characterized by complete loss of posterior structure as seen in hAHCYL1A mRNA-injected embryos (Fig. 8H), suggesting that function of AHCYL1A orthologs was largely conserved among species.

Dorsalized morphologies of zebrafish embryos were evident when the phosphatidylinositol cycle was inhibited (11). The phosphatidylinositol cycle is responsible for generating IP₃R-dependent intracellular Ca²⁺ release through the action of a second messenger, IP₃ (13). Because AHCYL1 binds to the IP₃R
we wondered whether overexpression of AHCYL1 in zebrafish embryo caused perturbation of intracellular Ca\(^{2+}\) release. Therefore, we cultured zebrafish embryos in the presence of thapsigargin and compared their morphology with those obtained after overexpression of hAHCYL1A (Figs. 8 and 9). Thapsigargin inhibits the Ca\(^{2+}\) ATPase-mediated return of Ca\(^{2+}\) into the endoplasmic reticulum, causing depletion of intracellular Ca\(^{2+}\) stores and inhibition of Ca\(^{2+}\) signaling pathways (14). Consistent with the report by Westfall et al. (11), we found that thapsigargin caused the majority of zebrafish embryos to display severe dorsalization (C4–C5 grade; Fig. 8I and Table 2), similar to AHCYL1A mRNA-injected embryos. Upon close inspection of moderately affected embryos (C1–C3 grade), both thapsigargin-treated and AHCYL1A mRNA-injected embryos displayed a reduced circulation (data not shown), loss of ventral tail fin tissue (Fig. 9, top panels), and thickened/twisted notochord (Fig. 9, bottom panels), all features associated with dorsalization. Control embryos treated with 0.1% Me\(_2\)SO (solvent control) had no morphological defects (data not shown). These data suggested that overexpression of hAHCYL1A interfered with the signaling pathways involved in phosphatidylinositol/Ca\(^{2+}\) signaling, inducing dorsalized phenotypes in zebrafish embryos.

**DISCUSSION**

AHCYL1 was presumed to be a protein with AHCY-like enzymatic activity because of its high protein identity with AHCY. We now provide evidence that AHCYL1 differs from AHCY both in its evolution and function. AHCY is a functionally conserved and ubiquitously expressed enzyme that catalyzes the reversible hydrolysis of S-adenosyl-L-homocysteine, the by-product of the S-adenosyl-L-homomethionine-dependent transmethylation reaction, into adenosine and homocysteine using NAD\(^+\) as a cofactor (2). AHCY is indispensable for the methylation reaction, because the accumulation of S-adenosylhomocysteine inhibits the methyltransferase activity. Deletion of the AHCY gene in mice results in early embryonic lethality (15), and in humans AHCY deficiency leads to severe growth restriction and developmental abnormalities (16). AHCY was thought to be a cytoplasmic enzyme, but it has been shown recently that AHCY translocates from the cytoplasm to the nucleus during cell culture as well as

---

**FIGURE 8.** Ectopic expression of AHCYL1 in zebrafish embryos induces dorsalization of the embryos similar to inositol phospholipid signaling pathway inhibition with thapsigargin (low power). **A**, wild-type (WT) embryos injected with EGFP mRNA (24 hpf). **B**, embryos injected with human AHCY mRNA (24 hpf). **C**, embryos injected with hAHCYL1 mRNA exhibited a moderate and severe phenotype (24 hpf). Note that hAHCYL1 mRNA-injected embryos show different morphological defects from human AHCY mRNA-injected embryos at 24 hpf. The right panel shows higher magnification of the severely affected embryo with axis duplication (each axis indicated by asterisks). **D**, wild-type embryos injected with EGFP mRNA; **E**, embryos injected with hAHCYL1 mRNA; **F**, embryos injected with zAHCYL1 mRNA (14-somite stage). The double-headed arrows indicate the distance between the head and tail bud. The arrowhead indicates the tail bud, protruding in human and zebrafish AHCYL1-injected embryos. Note that embryos injected with human AHCY mRNA and wild-type embryos do not show any increase in distance between the head and tail bud (12-somite stage). **H**, embryos injected with zAHCYL1 mRNA exhibited the moderate and severe phenotype at 24 hpf. **I**, embryos treated with thapsigargin at 24 hpf. Magnification is \( \times 25 \).
Role of AHCYL1 on Zebrafish Development

during X. laevis embryogenesis (17). Moreover, it complexes with mRNA (guanine-7-)methyltransferase and RNA polymerase II (18), further suggesting that AHCY contributes to fundamental cellular functions as well as embryonic development.

Protein sequences for AHCY orthologs have been identified from more than 30 different species, including bacteria, plants, and vertebrates (2). Our analysis of various prokaryotic and eukaryotic genomes revealed that the AHCl-like protein family members (AHCYL1 and AHCYL2) (1, 3) are only present in segmented multicellular organisms (i.e. vertebrates and insects but not nematode, yeast, malaria, and prokaryotes), whereas AHCY orthologs are present in all organisms examined (Table 3). Taken together with the phylogenetic analysis (Fig. 3), we concluded that AHCYL1 and AHCYL2 form an evolutionarily distinct family of molecules, which are likely to have evolved a novel function required in higher organisms. This fits with the finding that AHCYL1 lacks important residues found in AHCY that are necessary for AHCY enzymatic function (1).

Recently, an IP3R-binding protein isolated from a rat brain extract using an IP3R fusion protein affinity column was identified as AHCYL1 (6). AHCYL1 binding to IP3R was mediated by the N-terminal hydrophilic domain and abolished by alkali phosphatase treatment, suggesting that phosphorylation of AHCYL1 is essential for the binding. Because many putative Ser/Thr/Tyr phosphorylation sites in AHCYL1 N-terminal hydrophilic domain are conserved among species (Fig. 3), it is likely that the phosphorylation of this domain is important for AHCYL1 binding to IP3R. Although the functional consequence of AHCYL1 binding to IP3R has yet to be determined, it may modulate Ca2+ release by IP3R. The hydrolysis of phosphatidylinositol 4,5-bisphosphate in response to cell surface receptor activation results in the production of IP3, which in turn binds to IP3R to release Ca2+ stored in the endoplasmic reticulum. The resulting Ca2+ release regulates the activation of numerous downstream targets important for many cellular and developmental processes in all higher organisms, including fruit fly, zebrafish, and mouse (13, 19–21). For example, the increase of AHCYL1 mRNA that we observed in human DC is entirely consistent with Ca2+ signaling-mediated control of DC function (22–25).

Kume et al. (26) produced a series of monoclonal antibodies against Xenopus IP3R and showed that injection of these monoclonal antibodies into the ventral blastomeres of 4-cell stage Xenopus embryos converted ventral mesoderm to dorsal mesoderm, resulting in dorsalization of the embryos. Interestingly, no dorsalization was observed when these monoclonal antibodies were injected dorsally (26). Westfall et al. (11) further showed that injection of one of these monoclonal antibodies (clone 1G9) into zebrafish embryos induced dorsalization. Furthermore, depletion of intracellular Ca2+ by thapsigargin induced dorsalized zebrafish embryos (11). These results strongly suggest that the Ca2+ signaling mediated by IP3R is important for the normal development of ventral but not dorsal structures in developing embryos, and perturbation of ventral IP3R function induces dorsalization of embryos. We showed that morpholino suppression of zAHCYL1 induced ventralization of zebrafish embryos, and conversely AHCYL1 overexpression by mRNA injection

![FIGURE 9. Dorsalization of zebrafish embryos by zAHCYL1 mRNA injection is similar to inositol phospholipid signaling pathway inhibition with thapsigargin (magnification ×50). Ventral tails (upper panels) and notochords (lower panels) of wild-type (WT) embryos (left panels), zAHCYL1 mRNA-injected embryos (center panels), and thapsigargin-treated embryos (right panels) are shown. Note that both AHCYL1 mRNA-injected and thapsigargin-treated embryos show the loss of ventral tail tissue (single arrowheads in upper panels) and thickened/split notochord (double arrowheads in lower panels) when compared with wild-type embryos.](image)

### TABLE 2

Summary of zebrafish morphologies after mRNA injection or thapsigargin treatment

| Treatment             | n   | C1–C3 | C4–C5 | Other* | Normal  |
|-----------------------|-----|-------|-------|--------|---------|
| hAHCYL1 (1000 μg/ml)  | 97  | 42 (43.3%) | 12 (12.4%) | 43 (44.3%) |
| zAHCYL1A (1000 μg/ml) | 84  | 50 (59.5%) | 8 (9.5%) | 26 (31.0%) |
| aHCY (1000 μg/ml)     | 89  | 4 (4.5%) | 0 (0%) | 73 (82.0%) |
| GFP (1200 μg/ml)      | 130 | 1 (0.7%) | 0 (0%) | 122 (93.8%) |
| Thapsigargin (5 μM)   | 155 | 5 (3.2%) | 118 (76.1%) | 32 (20.6%) |

* Morphologies not seen in AHCYL1 microinjections.
TABLE 3
Distribution of AHCY and AHCYL genes in various organisms
Publicly available genome/EST databases were scanned for the presence of orthologs.

| Eukaryotic species | AHCY | AHCYL |
|--------------------|------|-------|
| P. falciparum (malaria) |       |       |
| C. elegans (nematode) |       |       |
| A. gambiae (mosquito) |       |       |
| D. melanogaster (fruit fly) |       |       |
| T. rubripes (fugu fish) |       |       |
| D. rerio (zebrafish) |       |       |
| X. laevis (frog) |       |       |
| G. gallus (chicken) |       |       |
| Mus musculus (mouse) |       |       |
| Homo sapiens (human) |       |       |

We isolated two alternative splice forms of zAHCYL1 differing only in their N-terminal sequences. Similar alternative splicing was documented for hAHCYL1 (Fig. 2). The N-terminal hydrophilic domain of AHCYL1 is essential for binding to the IP_{3}R (6), therefore it is possible that the differences in the N-terminal of the protein encoded by alternative 5’ exons may alter the binding affinity or specificity of the AHCYL1 molecule to different IP_{3}R isoforms. There are three known isoforms of IP_{3}R, which differ in their tissue distribution, IP_{3} sensitivity, and Ca^{2+} dependence (27). The second AHCY-like molecule, AHCYL2, has a very similar AHCY-like domain but quite a distinct N-terminal hydrophilic domain (1, 3). There is no information on AHCYL2 function or its IP_{3}R binding ability, but its high structural similarity to AHCYL1 suggests that it has a similar function. They may represent even further potential for differential and competitive regulatory binding capacity to the IP_{3}R isoforms, entirely consistent with the complexity of regulation of the crucial Ca^{2+} signaling pathway.

The mechanism of AHCYL1-binding to IP_{3}R and the subsequent IP_{3}R regulation of Ca^{2+} signaling is likely to be complex: (i) the binding of AHCYL1 to IP_{3}R requires phosphorylation of AHCYL1, probably mediated by protein kinases downstream of intracellular calcium release (e.g. protein kinase C, Ca^{2+}/calmodulin-dependent protein kinases, and/or the other protein kinases concomitantly activated with the inositol phospholipid signaling pathway), (ii) there is in excess of nonphosphorylated free AHCYL1 within the cytoplasm, (iii) protein phosphatases are also likely to play a role in maintaining the equilibrium between non-phosphorylated and phosphorylated AHCYL1, and (iv) these phosphatases must also be regulated within the inositol phospholipid signaling cascades. There are no AHCYL1-negative cell lines readily available for experimentation. This plus these complex interactions make it difficult to obtain direct evidence for AHCYL1 function. We are currently performing experiments that will address AHCYL1 function more directly, using cells from AHCYL1 gene-deleted mice.

Acknowledgments—We thank Ronald P. Gladue for advice. We also acknowledge Seema Khan and Kyle McDonald for technical assistance.

Note Added in Proof—Devogelaere et al. (28) showed recently that AHCYL1 binds directly to IP_{3}R and inhibits IP_{3} binding and IP_{3}-induced Ca^{2+} release.

REFERENCES
1. Dekker, J. W., Budhia, S., Angel, N. Z., Cooper, B. J., Clark, G. J., Hart, D. N., and Kato, M. (2002) Immunochemistry 35, 993–1001
2. Turner, M. A., Yang, X., Yin, D., Kuczera, K., Borchardt, R. T., and Howell, P. L. (2000) Cell Biochemistry. 33, 101–125
3. Nagase, T., Ishikawa, K., Suyama, M., Kikuno, R., Hirosawa, M., Miyajima, N., Tanaka, A., Hori, N., Nomura, N., and Ohara, O. (1998) J. Biol. Chem. 273, 355–364
4. Hart, D. N. J. (1997) Blood 90, 3245–3287
5. Banchereau, J., and Steinman, R. M. (1998) Nature 392, 245–252
6. Ando, H., Mizutani, A., Matsuura, T., and Mikoshiba, K. (2003) J. Biol. Chem. 278, 10602–10612
7. Blom, N., Gammeltoft, S., and Brunak, S. (1999) J. Mol. Biol. 294, 1351–1362
8. Westerfield, M. (1995) The Zebrafish Book: Guide for the Laboratory Use of Zebrafish (Danio rerio), 3rd Ed., University of Oregon Press, Eugene, OR
9. Kimbel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B., and Schilling, T. F. (1995) Dev. Dyn. 203, 253–310
10. Rupp, R. A., Snider, L., and Weintraub, H. (1994) Genes Dev. 8, 1311–1323
11. Westfall, T. A., Hjertos, B., and Slusarski, D. C. (2003) Dev. Biol. 259, 380–391
12. Mullins, M. C., Hammerschmidt, M., Kane, D. A., Odenthal, J., Brand, M., van Eden, F. J., Furutani-Seiki, M., Granato, M., Haftter, P., Heisenberg, C. P., Jiang, Y. J., Kelsh, R. N., and Nusslein-Volhard, C. (1996) Development 123, 81–93
13. Berridge, M. J. (1993) Nature 361, 315–325
14. Thastrup, O., Cullen, P. J., Drobak, B. K., Hanley, M. R., and Dawson, A. P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2466–2470
15. Miller, M. W., Duhl, D. M., Winke, B. M., Arredondo-Vega, F., Saxon, P. J., Wolff, G. L., Epstein, C. J., Hershfield, M. S., and Barsh, G. S. (1994) EMBO J. 13, 1806–1816
16. Baric, I., Fumic, K., Glenc, B., Cuk, M., Slabak, R., Fink, P., James, S. J., Mejaski-Bosnjak, V., Pazzini, L., Pogrzeby, P. I., Rados, M., Sarnavka, Y., Skuceanec-Spoljar, M., Allen, R. H., Stabler, S., Uzelac, L., Vugrek, O., Wagner, C., Zeisel, S., and Mudd, S. H. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 4234–4239
17. Radomski, N., Kaufmann, C., and Dreyer, C. (1999) Mol. Cell. Biol. 19, 4283–4290
18. Radomski, N., Barreto, G., Kaufmann, C., Yokoska, J., Mizumoto, K., and Dreyer, C. (2002) Biochim. Biophys. Acta 1590, 93–102
19. Mikoshiba, K., Furuto, T., and Miyawaki, A. (1994) Semin. Cell Biol. 5, 273–281
20. Swatton, J. E., Morris, S. A., Wissing, F., and Taylor, C. W. (2001) Biochem. J. 359, 435–441

4 M. Kato, K. McDonald, and D. Hart, unpublished results.
Role of AHCYL1 on Zebrafish Development

21. Koulen, P., Janowitz, T., Johnston, L. D., and Ehrlich, B. E. (2000) J. Neurosci. Res. 61, 493–499
22. Nardelli, B., Tiffany, H. L., Bong, G. W., Yourey, P. A., Morahan, D. K., Li, Y., Murphy, P. M., and Alderson, R. F. (1999) J. Immunol. 162, 435–444
23. Koski, G. K., Schwartz, G. N., Weng, D. E., Czerniecki, B. J., Carter, C., Gress, R. E., and Cohen, P. A. (1999) J. Immunol. 163, 82–92
24. Lyakh, L. A., Sanford, M., Chekol, S., Young, H. A., and Roberts, A. B. (2005) J. Immunol. 174, 2061–2070
25. Tenca, C., Merlo, A., Merck, E., Bates, E. E., Saverino, D., Simone, R., Zarcone, D., Trinchieri, G., Grossi, C. E., and Ciccone, E. (2005) J. Immunol. 174, 6757–6763
26. Kume, S., Muto, A., Inoue, T., Suga, K., Okano, H., and Mikoshiba, K. (1997) Science 278, 1940–1943
27. Thower, E. C., Hagar, R. E., and Ehrlich, B. E. (2001) Trends Pharmacol. Sci. 22, 580–586
28. Devogelaere, B., Nadif Kasri, N., Derua, R., Waelskens, E., Gallewaert, G., Missiaen, L., Parys, J. B., and DeSmedt, H. (2006) Biochem. Biophys. Res. Commun. 343, 49–56